Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Odanacatib - Merck & Co

Drug Profile

Odanacatib - Merck & Co

Alternative Names: MK-0822; MK-822

Latest Information Update: 14 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celera Group
  • Developer Banyu; Merck & Co
  • Class Amides; Biphenyl compounds; Cyclopropanes; Nitriles; Osteoporosis therapies; Small molecules; Sulfones
  • Mechanism of Action Bone resorption factor inhibitors; Cathepsin K inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bone metastases; Corticosteroid-induced osteoporosis; Male osteoporosis; Osteoarthritis; Osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 14 Nov 2019 Biomarkers information updated
  • 26 Sep 2016 Merck Sharp & Dohme terminates a phase I trial in Corticosteroid-induced osteoporosis (In adolescents, Prevention, In adults) in USA, United Kingdom, Italy and Finland (NCT01630616, EudraCT2012-003414-14)
  • 16 Sep 2016 Efficacy and adverse events data from an extension study of the phase III LOFT trial in Osteoporosis presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top